Von Hippel–Lindau (VHL) Syndrome

Von Hippel–Lindau (VHL) syndrome is an inherited condition that raises the lifetime risk of developing multiple tumors and cysts in different organs. These growths often include hemangioblastomas (benign, blood-vessel–rich tumors) in the brain, spinal cord, and retina (eye); kidney tumors (clear cell renal cell carcinoma and kidney cysts); adrenal gland tumors called pheochromocytomas; pancreatic cysts and neuroendocrine tumors; inner-ear tumors called endolymphatic sac tumors (ELSTs); and, in some people, epididymal or broad-ligament cystadenomas. VHL happens because of a change (pathogenic variant) in the VHL tumor-suppressor gene, which normally helps cells sense oxygen levels and keep blood-vessel growth in check. When VHL is damaged, the HIF (hypoxia-inducible factor) pathway stays overactive, pushing new blood vessels to grow and letting tumors form. VHL is autosomal dominant—one altered copy is enough to cause the condition—so first-degree relatives often need genetic counseling and screening. NCBIPMC

Von Hippel–Lindau (VHL) syndrome is an inherited condition that makes certain cells in the body grow too easily and form benign tumors (non-cancer growths) and cancers in more than one organ over a person’s lifetime. The most common tumors are hemangioblastomas (blood-vessel tumors) in the retina (back of the eye) and the brain/spinal cord, kidney cysts and kidney cancer (usually clear-cell renal cell carcinoma), adrenal gland tumors called pheochromocytomas (which release too much adrenaline-like hormones), pancreatic cysts and pancreatic neuroendocrine tumors, and inner-ear tumors called endolymphatic sac tumors (which can reduce hearing).

VHL happens because of a pathogenic change (mutation) in a gene named VHL, located on the short arm of chromosome 3 (3p25-26). The VHL gene makes the VHL protein (pVHL). This protein normally acts like a quality-control switch that tags HIF proteins (Hypoxia-Inducible Factors) for clean-up when oxygen is normal. When pVHL is missing or not working, HIF builds up and turns on many genes that push cells to make new blood vessels (angiogenesis) and to survive and grow when they should not. Over time, this “pro-growth, pro-blood-vessel” state allows tumors and cysts to form in different organs.

VHL is inherited in an autosomal dominant way. That means a person needs just one altered copy of the VHL gene (from either parent) to have the syndrome. Many people inherit it from a parent; others are the first in the family because the mutation occurred de novo (new) in them.

Two ideas are helpful in VHL:

• Penetrance: most people with a VHL mutation will develop at least one VHL-related tumor if they live long enough (high penetrance).

• Two-hit model: people are born with one altered VHL copy in all cells; when a cell later loses or inactivates the second, normal copy (“second hit”), a tumor can start in that organ.

Early diagnosis and regular surveillance (scheduled checks and scans) are the keys to preventing severe problems.

---

Types of VHL

Doctors sometimes group VHL into clinical subtypes because different mutation patterns tend to come with different tumor risks:

1. Type 1 VHL

   • High risk of retinal and central nervous system (CNS) hemangioblastomas and kidney tumors.

   • Low risk of pheochromocytoma.

   • Often linked to truncating mutations (nonsense/frameshift) or large deletions that “knock out” pVHL.

2. Type 2 VHL (pheochromocytoma-prone) — subdivided:

   • Type 2A: High pheochromocytoma risk; hemangioblastomas common; lower kidney cancer risk.

   • Type 2B: High pheochromocytoma risk and high kidney cancer risk; hemangioblastomas common.

   • Type 2C: Predominantly pheochromocytoma, often without other classic VHL tumors.

   • These forms often come from missense mutations (a single amino-acid change) that partially alter pVHL function rather than eliminating it.

These “types” help predict which organs need the closest watch and how often to screen.

---

Causes

Strictly speaking, there is one root cause of VHL syndrome: a pathogenic mutation in the VHL gene. However, many mechanisms and modifiers help explain why tumors form in different organs, when they appear, and how severe they become. Below are 20 causes/mechanisms/modifiers, written in simple language:

1. Germline VHL mutation (root cause)
   You are born with one altered copy of the VHL gene in every cell. This sets the stage for VHL.

2. Second hit (loss of heterozygosity)
   A cell later loses the remaining normal VHL copy (by deletion, mutation, or methylation). That “second hit” lets a tumor start in that organ.

3. HIF stabilization
   Without working pVHL, HIF-1α/2α are not removed. They pile up and switch on many genes that drive growth and blood-vessel formation.

4. Angiogenesis overdrive
   HIF turns on VEGF, PDGF, TGF-α, and related factors, bringing too many blood vessels into developing lesions (why hemangioblastomas are so vascular).

5. Metabolic rewiring
   HIF activation favors glycolysis and other survival pathways, helping cells grow in low-oxygen-like states even when oxygen is normal.

6. Different mutation classes

   • Truncating/large deletion variants often correlate with Type 1 (low pheo risk, higher RCC).

   • Missense variants often correlate with Type 2 (higher pheo risk).
     The exact mutation type helps “cause” a specific pattern of tumors.

7. Mosaicism
   If the mutation occurs early after conception, not all cells carry it equally. Patchy distribution can change which organs are affected and how severely.

8. De novo mutation
   Sometimes the altered VHL gene first appears in an individual (no family history). This explains sporadic cases.

9. Tissue-specific vulnerability
   Some organs (retina, cerebellum, spinal cord, kidney, adrenal, inner ear) are naturally more sensitive to HIF/angiogenesis signals, “causing” certain organ-specific tumors.

10. Local microenvironment
    Differences in local oxygen levels, blood flow, and support cells (stromal cells) can push lesions in some tissues to grow faster than in others.

11. Somatic co-mutations
    Tumors may pick up extra genetic changes beyond VHL loss. These extra hits can accelerate growth or change the tumor type (e.g., kidney cancer behavior).

12. Epigenetic changes
    Chemical tags on DNA (methylation) can silence the normal VHL copy or change expression of HIF target genes, promoting tumor formation.

13. Hypoxia-mimic signaling
    Even when oxygen is normal, HIF makes cells act like they are starved for oxygen. This false hypoxia helps tumors survive and recruit vessels.

14. EPO and erythrocytosis pathway
    Some VHL mutants increase erythropoietin (EPO), which can cause high red blood cell counts in certain variants and supports vascular growth.

15. Inflammatory signaling
    Chronic micro-inflammation and cytokines can support angiogenesis, helping lesions grow.

16. Hormonal/adrenergic stress in pheo tissue
    In adrenal medulla cells predisposed by VHL, stress signals can amplify catecholamine production, driving pheochromocytoma behavior (not the root cause, but a growth/symptom driver).

17. Aging and time
    The longer cells live, the more chances they have to lose the second VHL copy or gain extra changes—so risk rises with age.

18. Environmental co-factors (modifiers)
    Smoking, certain toxins, and radiation may increase kidney cancer risk or alter tumor behavior in people already carrying VHL.

19. Immune microenvironment
    Local immune cells and checkpoints can either hold back or permit tumor growth; permissive environments favor progression.

20. Surveillance gaps (practical cause of worse outcomes)
    When people with VHL miss regular screening, tumors are found later, which causes more complications—not the genetic cause, but a major clinical cause of harm.

---

Common symptoms

Not everyone has all of these. Symptoms depend on which organ has a tumor or cyst and how large it is. Many lesions are silent and found by routine screening.

1. Blurred vision or loss of vision
   Retinal hemangioblastomas can leak fluid or bleed, harming the macula (sharp-vision area) and causing vision loss if untreated.

2. Eye floaters or flashes
   Tiny bleeds or exudates near retinal vessels can cause new floaters or flashes—important warning signs to see an eye doctor quickly.

3. Headaches (often at the back of the head)
   Brain or cerebellar hemangioblastomas can raise pressure or irritate tissues, leading to persistent headaches.

4. Poor balance, unsteady walking (ataxia)
   Cerebellar lesions interfere with balance and coordination, causing clumsy gait or frequent stumbles.

5. Numbness, weakness, or tingling
   Spinal cord or brainstem hemangioblastomas can press on nerve pathways, causing weakness or sensory changes.

6. Sudden high blood pressure (spikes)
   Pheochromocytomas release bursts of adrenaline-like hormones, causing episodes of severe hypertension.

7. Pounding heartbeat (palpitations)
   The same hormone bursts can cause fast or irregular heartbeats during spells.

8. Heavy sweating, tremor, anxiety or panic-like episodes
   Typical pheochromocytoma symptoms, often with headache and palpitations in short attacks.

9. Blood in the urine (hematuria)
   Kidney tumors or cysts can bleed into the urinary tract. Even painless, it needs prompt evaluation.

10. Flank pain or a feeling of fullness in the side
    Large kidney cysts or tumors can stretch the kidney capsule, causing aching pain in the flank.

11. Unexplained weight loss or fatigue
    Can signal kidney cancer or pancreatic neuroendocrine tumor, especially with other local symptoms.

12. Hearing loss in one ear
    Endolymphatic sac tumors (inner ear) often cause progressive unilateral hearing loss; early detection helps preserve hearing.

13. Ringing in the ear (tinnitus) or ear fullness
    Pressure changes from inner-ear tumors create persistent ringing or a blocked sensation.

14. Vertigo (spinning) or balance spells
    Inner-ear involvement or cerebellar lesions can cause dizziness and spinning sensations.

15. Upper abdominal pain, pale stools, or jaundice (rare)
    Pancreatic tumors or cysts may block ducts, causing pain, digestive changes, or yellowing of eyes/skin.

---

Diagnostic tests

The goal is early finding and safe timing of treatment. A typical VHL program uses yearly or regular assessments tailored to the person’s age, mutation type, and prior findings.

A) Physical examination

1. Vital signs with orthostatic blood pressure
   Checking sitting/standing BP and pulse can catch pheochromocytoma-type surges (paroxysms) or sustained hypertension.

2. Focused neurological exam
   Tests of gait, finger-to-nose, heel-to-shin, eye movements, reflexes, strength, sensation help screen for cerebellar or spinal lesions.

3. Abdominal exam
   Gentle palpation can reveal tenderness or large masses; most early kidney or pancreatic lesions are not palpable, but the exam still matters.

4. Genitourinary exam (in adults)
   In men, epididymal papillary cystadenomas can present as painless scrotal masses; an exam may prompt ultrasound.

B) Manual/bedside tests

5. Visual acuity and confrontation visual fields
   Simple charts and finger-counting can detect vision loss or field defects, prompting urgent retina exam.

6. Direct/indirect ophthalmoscopy (dilated fundus exam)
   A clinician looks into the eye to find retinal hemangioblastomas, exudates, or new vessels—key for sight-saving care.

7. Bedside hearing tests (Weber/Rinne tuning fork)
   Quick checks suggest conductive vs sensorineural loss. If abnormal, formal audiology is arranged to evaluate for endolymphatic sac tumor.

8. Romberg test and tandem gait
   Simple balance maneuvers can pick up subtle cerebellar or proprioceptive problems.

C) Laboratory and pathological tests

9. Plasma free metanephrines
   The most sensitive blood test to screen for pheochromocytoma/paraganglioma in VHL. Elevated levels warrant imaging.

10. 24-hour urine fractionated metanephrines/catecholamines
    A confirmatory and complementary test that helps characterize hormone secretion patterns.

11. Urinalysis
    Checks for blood or protein in urine, which can suggest kidney involvement.

12. Serum creatinine and eGFR (± metabolic panel, CBC)
    Evaluates kidney function and broader health prior to contrast imaging or surgery.

13. Genetic testing for VHL
    Sequencing and deletion/duplication analysis (e.g., MLPA) confirm the germline mutation. Tumor testing can show the second hit. A positive result guides family testing and surveillance.

D) Electrodiagnostic tests

14. Electrocardiogram (ECG)
    Screens for arrhythmias during catecholamine surges and serves as pre-op baseline if pheochromocytoma is suspected.

15. Auditory Brainstem Response (ABR)
    Objective test of the hearing nerve and brainstem pathways; helps when standard audiometry is unclear or in young patients.

E) Imaging tests

16. MRI of brain and spine with contrast
    The gold standard to find hemangioblastomas in the cerebellum, brainstem, and spinal cord. MRI shows size, location, and mass effect, and helps plan timely surgery or laser/radiosurgery.

17. Retinal imaging: OCT and fluorescein angiography
    Optical Coherence Tomography (OCT) shows retinal layers and fluid; fluorescein angiography maps leaky vessels. Together they guide laser/cryotherapy/anti-VEGF decisions.

18. MRI abdomen with contrast (kidneys, pancreas, adrenals)
    Detects small renal cysts, early renal cell cancers, pancreatic cysts, pancreatic neuroendocrine tumors, and adrenal pheochromocytomas. MRI avoids radiation and is preferred for serial surveillance.

19. Renal and abdominal ultrasound
    A radiation-free way to follow known cysts/masses between MRIs, or when MRI is not available. Good for kidney size and cyst burden.

20. Functional tumor imaging for pheochromocytoma/paraganglioma
    If labs suggest pheo and MRI/CT needs clarification, doctors may use ^123I-MIBG scintigraphy or PET (e.g., ^68Ga-DOTATATE or ^18F-FDOPA) to localize active lesions and look for multifocal disease.

Non-pharmacological treatments (therapies and other measures)

Each item includes the goal (“Purpose”) and how it helps (“Mechanism”).

1. Genetic counseling and family testing
   Purpose: clarify risk for you and relatives; plan screening and child-bearing.
   Mechanism: confirms the specific VHL variant and guides who needs surveillance or prenatal options. NCBI

2. Structured, lifelong surveillance plan
   Purpose: find tumors early; prevent emergencies.
   Mechanism: scheduled eye exams, MRIs, abdominal imaging, and lab tests timed to the organs at risk. vhl.orgCancer.gov

3. Low-vision evaluation and aids (if retinal lesions impair sight)
   Purpose: preserve function and independence.
   Mechanism: magnifiers, contrast tools, orientation/mobility training.

4. Retinal laser photocoagulation (for small peripheral retinal hemangioblastomas)
   Purpose: control leaking lesions and protect vision.
   Mechanism: focused laser closes abnormal feeder vessels and starves the tumor. (Note: large/juxtapapillary lesions are harder; other methods may be needed.) PMCFrontiers

5. Retinal cryotherapy
   Purpose: treat select peripheral tumors not amenable to laser.
   Mechanism: freezing causes tumor necrosis while aiming to spare surrounding retina. PMC

6. Photodynamic therapy (PDT) in select cases
   Purpose: an option for difficult retinal lesions when expert centers judge benefit.
   Mechanism: light-activated drug damages tumor vasculature; effectiveness varies for larger lesions. PMC

7. Pars plana vitrectomy with adjuncts (for traction, exudation, or non-resolving issues)
   Purpose: restore or stabilize retinal anatomy/vision.
   Mechanism: removes vitreous traction, applies intraoperative laser/cryotherapy as needed. Frontiers

8. Microsurgical removal of CNS hemangioblastomas
   Purpose: relieve mass effect, prevent neurologic decline.
   Mechanism: en bloc resection of well-circumscribed vascular tumors; timing guided by growth and symptoms. PMC

9. Stereotactic radiosurgery for select CNS lesions
   Purpose: treat small, surgically challenging hemangioblastomas or adjuvant control.
   Mechanism: focused radiation arrests tumor cell division and vessel growth; used case-by-case. PMC

10. Definitive surgery for ELST (inner-ear tumor)
    Purpose: stop progressive hearing loss/vertigo and local invasion.
    Mechanism: skull-base resection removes tumor; adjuvant radiosurgery may be considered in selected scenarios at expert centers. ScienceDirectPMC

11. Partial nephrectomy (“nephron-sparing surgery”) for kidney tumors
    Purpose: cure localized RCC while preserving kidney function because new tumors can arise later.
    Mechanism: removes tumor with a margin, keeping as much kidney as possible. Cloudfront

12. Thermal ablation for small renal tumors (radiofrequency or cryoablation, case-selected)
    Purpose: treat small masses when surgery is less desirable.
    Mechanism: heat or freeze destroys tumor cells under image guidance. European Urology

13. Adrenalectomy for pheochromocytoma/paraganglioma
    Purpose: cure catecholamine-secreting tumors and prevent hypertensive crises.
    Mechanism: laparoscopic or open removal after proper pre-op blockade (see Drug section). NCBI

14. Pancreatic surgery for VHL-related neuroendocrine tumors (PanNETs)
    Purpose: reduce risk of metastasis when size or features suggest higher risk.
    Mechanism: enucleation or formal pancreatectomy based on location/size; often recommended when >3 cm in VHL. PMC

15. Audiology and vestibular rehabilitation
    Purpose: improve hearing/communication and balance in ELST-related deficits.
    Mechanism: hearing aids, assistive devices, and exercises retrain balance pathways. vhl.org

16. Fertility and pregnancy planning
    Purpose: minimize maternal/fetal risk from undiagnosed tumors (e.g., pheochromocytoma).
    Mechanism: preconception counseling, updated imaging, and team-based planning. Cancer.gov

17. Blood pressure self-monitoring
    Purpose: catch surges that may signal pheochromocytoma.
    Mechanism: regular home readings prompt timely testing for catecholamine excess. NCBI

18. Headache/neurologic symptom diary
    Purpose: flag changes suggesting CNS tumor growth or increased pressure.
    Mechanism: structured tracking supports earlier imaging and intervention.

19. Lifestyle heart-health measures (smoking cessation, movement, weight management)
    Purpose: protect kidneys/heart, lower surgical risk.
    Mechanism: reduces cardiovascular and metabolic stress that can complicate care.

20. Psychological support and peer groups
    Purpose: reduce stress, improve coping in a lifelong condition.
    Mechanism: counseling and VHL community resources connect you with experienced teams and families. vhl.org

---

Drug treatments

Doses are typical adult regimens; individual plans must be set by your clinicians.

1. Belzutifan (Welireg) — HIF-2α inhibitor
   Class: targeted therapy (HIF-2α inhibitor).
   Dose & timing: 120 mg orally once daily, with or without food.
   Purpose: treat VHL-associated RCC, CNS hemangioblastomas, and pancreatic neuroendocrine tumors that do not need immediate surgery.
   Mechanism: blocks overactive HIF-2α signaling downstream of the VHL defect, shrinking or stabilizing tumors and reducing angiogenesis.
   Key side effects: anemia, fatigue, hypoxia, headache; drug-drug interactions (UGT2B17/CYP2C19 inhibitors). Clinicians monitor hemoglobin and oxygen saturation and adjust dose if needed. U.S. Food and Drug AdministrationFDA Access DataPMC

2. Phenoxybenzamine — nonselective α-blocker (pre-op for pheochromocytoma)
   Class: nonselective, irreversible α-adrenergic blocker.
   Dose & timing: often 10 mg twice daily, titrated every few days to blood-pressure/heart-rate targets for 7–14 days before surgery (center-specific).
   Purpose: prevent dangerous hypertensive crises during tumor handling.
   Mechanism: blocks α-receptors to blunt catecholamine effects.
   Side effects: orthostatic hypotension, nasal stuffiness, fatigue. (Some centers use selective α1 blockers instead; see below.) NCBIClinicalTrials.gov

3. Doxazosin (or prazosin/terazosin) — selective α1-blocker
   Class: selective α1-adrenergic blocker.
   Dose & timing: start 1 mg nightly and titrate; used pre-op similar to phenoxybenzamine per institutional protocol.
   Purpose: alternative α-blockade with potentially fewer side effects.
   Mechanism: selective α1 inhibition lowers vascular tone.
   Side effects: dizziness, hypotension. (Note: evidence for mandatory pre-op α-blockade is mixed, but many centers still use it.) NCBIPMC

4. Propranolol (or other β-blocker) — add after α-blockade
   Class: β-adrenergic blocker.
   Dose & timing: e.g., 10–40 mg three times daily, added only after adequate α-blockade if tachycardia persists.
   Purpose: control heart rate and arrhythmias before pheochromocytoma surgery.
   Mechanism: blocks β-receptors; prevents catecholamine-induced tachycardia.
   Side effects: bradycardia, fatigue, bronchospasm (avoid in asthma). NCBI

5. Metyrosine — catecholamine synthesis inhibitor
   Class: tyrosine hydroxylase inhibitor.
   Dose & timing: start 250 mg 3–4×/day, titrate (short-term adjunct pre-op in selected cases).
   Purpose: reduce catecholamine production when α/β-blockade alone is insufficient.
   Mechanism: lowers synthesis of epinephrine/norepinephrine.
   Side effects: sedation, depression, extrapyramidal symptoms; used by experienced teams. NCBI

6. Sunitinib — VEGFR/PDGFR TKI (for RCC or PanNETs in select cases)
   Class: multi-targeted tyrosine kinase inhibitor.
   Dose & timing: RCC standard 50 mg daily on 4-weeks-on/2-weeks-off schedule; 37.5 mg daily continuous is used for PanNETs.
   Purpose: systemic therapy for advanced RCC; may be used for progressive PanNETs when indicated.
   Mechanism: blocks angiogenesis and tumor growth signaling.
   Side effects: fatigue, hypertension, hand-foot syndrome, mucositis. (Systemic therapy is usually reserved for advanced disease; localized tumors in VHL are often managed surgically/locally first.) CloudfrontPMC

7. Pazopanib — VEGFR TKI (RCC)
   Class: tyrosine kinase inhibitor.
   Dose & timing: 800 mg orally once daily (typical).
   Purpose: alternative first-line or later-line therapy in RCC per guidelines; individualized in VHL context.
   Mechanism: anti-angiogenic.
   Side effects: liver enzyme elevations, hypertension, diarrhea, hair color change. Cloudfront

8. Everolimus — mTOR inhibitor (PanNETs; sometimes RCC)
   Class: mTOR pathway inhibitor.
   Dose & timing: 10 mg orally once daily (adjust for toxicity).
   Purpose: slows progression of advanced PanNETs; sometimes used in RCC.
   Mechanism: inhibits mTOR-driven growth and angiogenic signaling.
   Side effects: mouth ulcers, rash, infections, hyperglycemia, hyperlipidemia. PMC

9. Octreotide LAR / Lanreotide — somatostatin analogs (functioning PanNETs)
   Class: somatostatin receptor agonists.
   Dose & timing: Octreotide LAR 20–30 mg IM every 4 weeks; Lanreotide 120 mg deep-SC every 4 weeks, titrated per response.
   Purpose: control hormone symptoms and, in some cases, slow tumor growth.
   Mechanism: suppresses hormone secretion; may have anti-proliferative effects.
   Side effects: gallstones, steatorrhea, glucose changes. PMC

10. Intravitreal anti-VEGF (bevacizumab/ranibizumab) — adjunct for retinal disease
    Class: anti-angiogenic monoclonal antibodies.
    Dose & timing: e.g., bevacizumab 1.25 mg or ranibizumab 0.5 mg intravitreal at retina specialist’s discretion (often as adjunct to laser/cryotherapy).
    Purpose: reduce leakage/edema and help stabilize vision in select cases; effectiveness varies with lesion size/location.
    Mechanism: neutralizes VEGF, reducing abnormal vessel permeability.
    Side effects: rare endophthalmitis, transient pressure rise. PMCFrontiers

Important: Drug choices in VHL depend on which organ is affected, tumor size, growth, symptoms, and whether surgery is preferred. Systemic therapy is not a one-size-fits-all decision and should be made in a multidisciplinary clinic.

---

Dietary “molecular” supplements

These DO NOT treat VHL itself. They may support general health while you follow a medical plan.

1. Omega-3 fatty acids (EPA/DHA) — 1–2 g/day combined EPA+DHA (with meals). Supports heart and vascular health; anti-inflammatory lipid mediators may modestly reduce endothelial activation.

2. Vitamin D3 — dose guided by blood level (often 1,000–2,000 IU/day). Supports bone and immune function; avoids deficiency that can complicate recovery.

3. Magnesium — 200–400 mg/day (as glycinate/citrate). Aids muscle/nerve function and blood pressure control; deficiency can worsen cramps or arrhythmias.

4. B-complex (with B12/folate) — standard daily dose. Supports hematologic and nerve health; some cancer drugs affect mucosa where B-vitamins help maintenance.

5. Lutein + Zeaxanthin — 10 mg + 2 mg/day. Eye-friendly carotenoids that concentrate in the macula; may support retinal resilience.

6. Coenzyme Q10 — 100–200 mg/day with fat. Mitochondrial cofactor that may help fatigue in some people; interacts with anticoagulants—discuss with your team.

7. Probiotic foods or capsules — live cultures daily. Supports gut health, which can be affected by TKIs or somatostatin analogs.

8. Curcumin (standardized) — 500–1,000 mg/day with piperine unless on anticoagulation. Anti-inflammatory signaling support; discuss drug interactions.

9. N-acetylcysteine (NAC) — 600 mg 1–2×/day. Precursor to glutathione; antioxidant support during periods of oxidative stress.

10. Melatonin — 1–3 mg at bedtime if sleep is poor. Regulates sleep; good sleep helps cognition and immune regulation.

Always clear supplements with your clinicians—many cancer and anesthesia drugs have interactions or require kidney/liver checks.

---

Regenerative-focused” therapies

There are no approved “stem cell drugs” for VHL. Below are immune-targeted or regenerative-research directions, with honest status notes.

1. Nivolumab (immune checkpoint inhibitor, anti–PD-1)
   Dose: common regimens include 240 mg IV every 2 weeks or 480 mg IV every 4 weeks in RCC (not specific to VHL).
   Function/mechanism: lifts immune “brakes” so T-cells can attack RCC.
   Status: established for sporadic/metastatic RCC; used case-by-case in VHL-related advanced RCC. Side effects include immune-mediated colitis, thyroiditis, hepatitis—requires close monitoring. Cloudfront

2. Pembrolizumab (anti–PD-1)
   Dose: 200 mg IV every 3 weeks or 400 mg every 6 weeks in RCC combinations.
   Function/mechanism: similar to nivolumab; part of modern RCC regimens.
   Status: for advanced RCC; suitability in VHL depends on disease stage and prior therapies. Cloudfront

3. Belzutifan (listed above)
   Dose: 120 mg daily.
   Function: targets the HIF-2α pathway central to VHL biology—this is the targeted drug specifically approved for VHL-associated tumors.
   Status: FDA-approved; not “regenerative,” but disease-biology-directed. U.S. Food and Drug Administration

4. Adoptive cellular therapy / tumor-infiltrating lymphocytes (TILs)
   Dose: investigational protocols only.
   Function: expand a patient’s own antitumor T-cells outside the body and infuse them back.
   Status: Experimental for RCC; not standard for VHL—only in clinical trials.

5. Gene-editing approaches (e.g., CRISPR-based VHL repair)
   Dose: research only.
   Function: corrects the germline VHL variant in lab models; goal is to restore normal HIF control.
   Status: Pre-clinical/early research—not available as therapy.

6. Retinal/inner-ear regenerative research
   Dose: none; research only.
   Function: stem-cell–derived retinal pigment epithelium or hair-cell regeneration to restore vision/hearing.
   Status: Experimental; not proven for VHL at this time.

Bottom line: the only approved, VHL-specific targeted medicine is belzutifan. Immune checkpoint drugs are options for advanced RCC, tailored to the individual. Beware of any clinic advertising “stem cell cures” for VHL—those are unproven.

---

Surgeries

1. Partial nephrectomy (kidney-sparing surgery)
   Procedure: remove the renal tumor with a small margin, often laparoscopic/robotic; reconstruct the kidney.
   Why: preserves kidney tissue because new tumors can appear later; cures localized RCC. Cloudfront

2. Adrenalectomy (for pheochromocytoma)
   Procedure: laparoscopic or open removal after careful α- then β-blockade and volume expansion.
   Why: removes the source of dangerous catecholamines to prevent hypertensive crises and complications. NCBI

3. CNS hemangioblastoma resection
   Procedure: microsurgical removal using vascular control techniques; sometimes staged if multiple lesions.
   Why: relieve mass effect, protect neurologic function, prevent hemorrhage. PMC

4. Endolymphatic sac tumor (ELST) resection
   Procedure: skull-base approach by otology/neurosurgery team; aim for gross total resection; radiosurgery may be adjunct.
   Why: halt progressive hearing loss/vertigo and local skull-base destruction. ScienceDirect

5. Pancreatic tumor surgery (enucleation or pancreatectomy)
   Procedure: remove the neuroendocrine tumor—enucleate if small and away from ducts; do distal pancreatectomy or Whipple for larger/complex cases.
   Why: PanNETs >3 cm in VHL carry higher metastatic risk; surgery reduces that risk. PMC

---

Prevention & self-care strategies

1. Follow your personalized surveillance calendar—no gaps. Missing screens is the #1 preventable risk. vhl.orgCancer.gov

2. Know urgent red flags (sudden severe headache, vision changes, new neurologic weakness/numbness, resistant high BP, spells of palpitations/sweating/headache). Seek emergency care. NCBI

3. Avoid smoking and manage blood pressure, lipids, and glucose to protect kidneys/heart and surgical fitness. Cloudfront

4. Discuss pregnancy early with your team for targeted preconception checks. Cancer.gov

5. Use protective eyewear during activities that risk eye injury; report new floaters, flashes, or visual field loss fast. Frontiers

6. Keep an updated medication list—belzutifan and TKIs have interactions; share with every clinician/pharmacist. FDA Access Data

7. Stay physically active within limits your neurologist/rehab team sets; avoid activities that strain if you have active CNS/retinal lesions.

8. Vaccinations up to date (per national schedules) to reduce infection-related setbacks during treatments.

9. Mental health care—counseling, peer groups, stress-reduction programs reduce burnout in chronic care. vhl.org

10. Second opinions at VHL-experienced centers for complex surgical decisions.

---

When to see a doctor urgently vs. routinely

• Urgently (same day / emergency):
  sudden, worst-ever headache; new weakness, numbness, or trouble walking; sudden or rapidly worsening vision; seizure; blood pressure spikes with pounding headache/palpitations/sweats; severe abdominal pain; fainting. These can signal hemorrhage, rising intracranial pressure, retinal complications, or an undiagnosed pheochromocytoma. NCBI

• Prompt appointment (days to a week):
  persistent new headaches, balance/coordination changes, new hearing loss/ear fullness, new visual floaters or a “curtain,” rising home BP, unexplained weight loss. vhl.org

• Routine follow-up (per your plan):
  scheduled eye exams, brain/spine MRI, abdominal imaging, catecholamine testing, audiology, dermatologic and dental checks, and genetic counseling touchpoints. vhl.orgCancer.gov

---

What to eat and what to avoid

1. Base meals on plants and lean proteins. Plenty of vegetables, fruits, legumes, whole grains, fish, and poultry support heart-kidney health during lifelong care.

2. Hydrate consistently (adjust per kidney function and clinician advice). Good hydration helps blood pressure and recovery.

3. Limit ultra-processed foods, excess sugar, and refined carbs. They worsen weight, lipids, and energy.

4. Moderate sodium (often <2 g/day sodium, or ~5 g salt, if your doctor agrees) to help blood pressure—important if pheochromocytoma is suspected/treated.

5. Healthy fats (olive oil, nuts, seeds) over saturated/trans fats to support vessels and lipids.

6. Adequate protein—but if kidney function declines, your nephrologist may restrict protein.

7. Alcohol sparingly or not at all; avoid with interacting drugs or if blood pressure is an issue.

8. Caffeine in moderation; heavy caffeine can worsen palpitations/anxiety in catecholamine-prone states.

9. Food safety vigilance during immunotherapy/targeted therapy (wash produce, avoid undercooked meats) to cut infection risk.

10. Supplement choices only after checking for drug interactions (see the supplement list; many interact with anticoagulants or TKIs). Cloudfront

---

FAQs

1) Is VHL cancer?
VHL itself is not cancer; it’s a genetic condition that increases the risk of certain tumors (some benign, some malignant), especially clear cell kidney cancer. NCBI

2) If I feel fine, do I really need screening?
Yes. Many VHL tumors are silent at first. Screening catches them early, when treatment is safer and vision/organ function can be saved. vhl.orgCancer.gov

3) What is the biggest VHL breakthrough lately?
The approval of belzutifan, the first drug to directly target the HIF-2α pathway that is overactive in VHL. It can treat VHL-related RCC, CNS hemangioblastomas, and pancreatic NETs that don’t need immediate surgery. U.S. Food and Drug Administration

4) Will belzutifan replace surgery?
Not usually. In VHL, local treatment (e.g., kidney-sparing surgery, eye procedures) is still critical. Belzutifan helps when surgery isn’t needed yet or is not feasible. Your team decides case by case. U.S. Food and Drug AdministrationCloudfront

5) Are immune checkpoint drugs “immune boosters”?
No. They remove immune brakes and can cause the immune system to attack normal tissues too. They are powerful cancer drugs, not vitamins or general boosters. Cloudfront

6) Can I cure VHL with stem cells?
No. There are no approved stem-cell cures for VHL. “Stem cell clinics” offering cures are not evidence-based. Research into gene correction and regeneration is ongoing, but not clinical standard. (Ask about legitimate clinical trials if you’re interested.)

7) How often will I need MRIs or eye exams?
Schedules vary by age and findings. Many people have annual eye exams, periodic brain/spine MRIs, and abdominal imaging at intervals defined by guidelines and your prior scans/labs. vhl.orgCancer.gov

8) I’m planning a pregnancy. What should I do?
Meet your VHL team before trying to conceive. They’ll update imaging and labs (especially to rule out pheochromocytoma) and outline safe monitoring during pregnancy. Cancer.gov

9) What is the kidney-sparing threshold?
Because multiple kidney tumors can arise over time, nephron-sparing approaches are favored whenever appropriate; thermal ablation is sometimes used for small masses. Decisions are individualized with an RCC/VHL specialist team. CloudfrontEuropean Urology

10) I have hearing changes—could it be VHL?
Possibly. ELSTs can cause hearing loss, tinnitus, or vertigo. ENT/audiology evaluation and inner-ear MRI are important in VHL. ScienceDirect

11) What eye treatments protect vision?
Small peripheral lesions: laser or cryotherapy; complex or larger lesions may need surgery or adjunct anti-VEGF. Early detection improves outcomes. PMCFrontiers

12) Do certain foods make tumors grow?
No specific food causes VHL tumors. Focus on overall cardiometabolic health and discuss any supplements for drug interactions.

13) Are kids screened?
Yes—age-specific schedules exist for at-risk children, often starting with eye exams and blood pressure, then imaging at recommended ages under specialist guidance. vhl.org

14) Can I exercise?
Usually yes, but your plan should match your current lesions and surgical history. Avoid activities that risk head/eye trauma or strain if you have active CNS or retinal disease.

15) Where can I find trustworthy resources?
The VHL Alliance handbook and surveillance sheets and the NCI PDQ pages are excellent, up-to-date starting points to bring to clinic visits. vhl.orgCancer.gov

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 30, 2025.